Resilience purchases Ohio biomanufacturing site from AstraZeneca
Biotech manufacturing pioneer Resilience said Tuesday afternoon that it is purchasing an Ohio-based manufacturing site from AstraZeneca and building a new partnership with the UK-based pharma.
The facility is based in the town of West Chester, OH, just north of Cincinnati. Resilience will produce “select” AstraZeneca medicines at the facility as part of the supply agreement. The financial terms of the agreement weren’t disclosed, but the deal is expected to close early next year.
By acquiring the West Chester plant, Resilience will get all the site’s physical assets, retain its leadership and around 500 employees, and plan to invest in the workforce and the wider facility.
The site itself is around 580,000 square feet and is equipped with many manufacturing capabilities, including aseptic filling, inspection, packaging, cold-chain operations, autoinjectors, and a virtual reality training center.
“We envision the West Chester site as our global center of excellence for commercial drug product manufacturing that will produce a wide range of life-saving medicines,” said Resilience CEO Rahul Singhvi in a statement.
Resilience and AstraZeneca also announced on Tuesday that both companies will establish a long-term biomanufacturing relationship to support AstraZeneca’s portfolio, with AstraZeneca gaining access to Resilience’s end-to-end manufacturing services.
The addition of the West Chester site now gives Resilience close to two million square feet of biomanufacturing space.
And this move also comes during a period of rapid expansion for Resilience. After grabbing $625 million in Series D financing this summer, the company quickly inked deals with MD Anderson and the Mayo Clinic to establish manufacturing operations at the medical centers to try and quickly turn around the production of therapies.